cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo Nordisk's CagriSema outperforms Ozempic – cagrisema semaglutide cagrilintide phase 3

Hypoglycaemia (low blood glucose) is uncommon when Ozempic is used as monotherapy, as its glucose-lowering effect is glucose-dependent

Studies show that subjects infused with GHRP-2 consumed significantly more calorieseating 136.0 13.0 kJ/kg compared to 101.3 10.5 kJ/kg with placebo

See our prior blog GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List, dated October 23, 2024

If you feel more nauseated when increasing doses, go for a slow titration and schedule small, bland protein snacks instead of skipping doses

The consequences are significant: accelerated muscle loss, a soft flabby appearance despite weight loss, reduced metabolic rate, weakened immune function, hair loss, and poor recovery from exercise